Skip to content

metabolomics study related to the treatment of abnormal bone metabolism in Turner syndrome

metabolomics study related to the treatment of abnormal bone metabolism in Turner syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045208
Enrollment
Unknown
Registered
2021-04-08
Start date
2021-04-02
Completion date
Unknown
Last updated
2021-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

turner syndrome

Interventions

Pre-treatment group and post-treatment group:Estrogen progesterone supplementation group
Control group:none

Sponsors

Guangzhou Women and Children Medical Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
5 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Turner syndrome was confirmed by karyotype analysis of peripheral blood; 2. BMD-Z value <= -2.0 as measured by DXA; 3. With the consent of the patient or his guardian, and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Other chronic bone diseases that may affect BMD, such as osteochondroplasia and malignant bone disease; 2. Other diseases that may affect BMD, such as: endocrine disease (parathyroid function already, hyperthyroidism, pituitary function decline, Cushing's syndrome, type 1 and type 2 diabetes, anorexia, androgen resistance syndrome, hypercalciuria), gastrointestinal disease, inflammatory bowel disease, gastrointestinal bypass, or other operations, primary biliary cirrhosis, pancreatic disease, celiac disease, malabsorption) and blood system diseases, multiple myeloma, leukemia, lymphoma, monoclonal immunoglobulin, hemophilia, sickle cell anemia, systemic mastocytosis, globin generation barrier anemia), rheumatoid immune disease, rheumatoid arthritis, system, lupus erythematosus, ankylosing spondylitis), chronic metabolic acidosis, end-stage renal disease, congestive heart failure, sarcoidosis, idiopathic scoliosis, etc. 3. Recent use of thyroid hormones, glucocorticoids, thiazolidinedione insulin sensitizers, aromatase inhibitors, heparin, acid suppressants and other drugs and health care products that affect BMD; 4. Smoking, long-term drinking of coffee or caffeinated beverages, excessive drinking (more than two units of ethanol per day, equivalent to 1 jin of beer, 3 liang of wine or 1 liang of spirits), nutritional imbalance and other bad lifestyles.

Design outcomes

Primary

MeasureTime frame
Metabolites;Bone metabolism index;

Secondary

MeasureTime frame
Bone density level;

Countries

China

Contacts

Public ContactLi Li

Guangzhou Women and Children Medical Center

lilyli1973@126.com+86 13902331656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026